TRDA — Entrada Therapeutics Share Price
0.000.00%
Last trade - 00:00- $350.31m
- -$69.69m
- $210.78m
- 67
- 96
- 56
- 86
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.82 | ||
| Price to Tang. Book | 0.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.66 | ||
| EV to EBITDA | -1.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.66% | ||
| Return on Equity | 19.56% | ||
| Operating Margin | 22.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 129.01 | 210.78 | 36.68 | 28.21 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Directors
- Dipal Doshi PRE
- Kory Wentworth CFO (42)
- Nathan Dowden COO
- Natarajan Sethuraman CSO
- Jared Cohen GCN
- Peter Kim DRC
- Mary Thistle DRC (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 22nd, 2016
- Public Since
- October 29th, 2021
- No. of Shareholders
- 20
- No. of Employees
- 183
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 37,953,417
- Address
- One Design Center Place, Suite 17-500, BOSTON, 02210
- Web
- https://www.entradatx.com/
- Phone
- +1 8573051825
- Auditors
- Ernst & Young LLP
Upcoming Events for TRDA
Entrada Therapeutics Inc Annual Shareholders Meeting
Entrada Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Entrada Therapeutics Inc Earnings Release
Q3 2025 Entrada Therapeutics Inc Earnings Release
Similar to TRDA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Entrada Therapeutics share price?
As of Today at 20:29 UTC, shares in Entrada Therapeutics are trading at $9.23. This share price information is delayed by 15 minutes.
How has the Entrada Therapeutics share price performed this year?
Shares in Entrada Therapeutics last closed at $9.23 and the price had moved by -31.93% over the past 365 days. In terms of relative price strength the Entrada Therapeutics share price has underperformed the S&P500 Index by -38.62% over the past year.
What are the analyst and broker recommendations for Entrada Therapeutics?
The overall consensus recommendation for Entrada Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Entrada Therapeutics dividend yield?
Entrada Therapeutics does not currently pay a dividend.
Does Entrada Therapeutics pay a dividend?
Entrada Therapeutics does not currently pay a dividend.
When does Entrada Therapeutics next pay dividends?
Entrada Therapeutics does not currently pay a dividend.
How do I buy Entrada Therapeutics shares?
To buy shares in Entrada Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Entrada Therapeutics?
As of the previous close price of $9.23, shares in Entrada Therapeutics had a market capitalisation of $350.31m.
Where are Entrada Therapeutics shares listed?
Here are the trading details for Entrada Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TRDA
What kind of share is Entrada Therapeutics?
Based on an overall assessment of its quality, value and momentum Entrada Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Entrada Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Entrada Therapeutics is $24.33. That is 163.6% above the last closing price of $9.23.
Analysts covering Entrada Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.41 for the next financial year.
Find out moreWhat is the trend in the Entrada Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Entrada Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -47.32%.
As of the last closing price of $9.23, shares in Entrada Therapeutics were trading -37.12% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Entrada Therapeutics PE Ratio?
The Entrada Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Entrada Therapeutics?
Entrada Therapeutics' management team is headed by:
- Dipal Doshi - PRE
- Kory Wentworth - CFO
- Nathan Dowden - COO
- Natarajan Sethuraman - CSO
- Jared Cohen - GCN
- Peter Kim - DRC
- Mary Thistle - DRC